32 results
S-1
EX-4.2
SPRY
ARS Pharmaceuticals Inc
10 Nov 20
IPO registration
4:46pm
anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates to) cease all … , or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries
DRS
EX-4.2
SPRY
ARS Pharmaceuticals Inc
2 Oct 20
Draft registration statement
12:00am
anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates to) cease all … , or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries
8-K
EX-10.4
SPRY
ARS Pharmaceuticals Inc
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
actions that are prohibited by local and other anti-corruption laws (collectively Anti-Corruption Laws) that may be applicable to either or both Parties … in a manner that would violate Anti-Corruption Laws;
(iii)
it shall, on request by the other Party, verify in writing that to the best of such Party’s
8-K
SPRY
ARS Pharmaceuticals Inc
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
, or (6) a violation by the other party of trade control or anti-corruption laws.
The foregoing description of the Renaissance Agreement is not complete
8-K
EX-10.5
SPRY
ARS Pharmaceuticals Inc
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
by either party of a trade control law and/or an anti-corruption law, including the U.S. Foreign Corrupt Practices Act, shall be grounds for immediate
S-1/A
EX-1.1
qzw f60pd
30 Nov 20
IPO registration (amended)
6:06am
10-Q
7gsc81x8 xf5
13 May 21
Quarterly report
4:21pm
8-K
EX-10.3
p1u7s471w7km5339lxm
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
10-K
0qcn5hbtjp0g0jlo
29 Mar 21
Annual report
4:13pm